1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Mental Health Analysis & Statistics 2022 - United Kingdom (p5)

Mental Health Analysis & Statistics 2022 - United Kingdom (p5)

121-150 of about 100 reports

Neurostimulation Devices Market (2nd Edition), 2018-2030

  • $ 3499
  • September 2018
  • 639 pages

INTRODUCTION The National Academy of Medicine indicates that as many as 100 million people in the US suffer from some form of pain, which has been shown to be associated with a socioeconomic burden of ...

  • United States
  • APAC
  • Chronic Pain
  • Neurological Disorder
  • Industry analysis
  • Drug Approval

Podiatry Services Global Market Strategies and Opportunities to 2021

  • $ 4000
  • July 2018
  • 352 pages

Podiatrists are physicians or surgeons specializing in preventing, diagnosing and treating conditions of lower extremities such as feet and ankle.Podiatrists offer comprehensive care for all situations ...

  • APAC
  • World
  • Musculoskeletal Disorder
  • Cardiovascular Disease
  • Industry analysis
  • Health Provider Density
  • Dates Consumption

EPIOMIC EPIDEMIOLOGY SERIES: FRONTOTEMPORAL LOBE DEMENTIA FORECAST IN 19 MAJOR MARKETS 2018–2028

  • $ 5577
  • July 2018
  • 70 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Frontotemporal Lobe Dementia in 19 Major Markets Frontotemporal lobe dementia (FTD) is a progressive degenerative disorder characterised ...

  • South Korea
  • Japan
  • Dementia
  • Epidemiology
  • Industry analysis
  • Dementia Prevalence
  • Life Expectancy

EPIOMIC EPIDEMIOLOGY SERIES: GAUCHER’S DISEASE FORECAST IN 30 MAJOR MARKETS 2018–2028

  • $ 5577
  • July 2018
  • 120 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Gaucher’s Disease in 30 Major Markets Gaucher’s Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA ...

  • South Korea
  • India
  • Neurological Disorder
  • Industry analysis
  • Life Expectancy
  • Cancer Incidence

EPIOMIC EPIDEMIOLOGY SERIES: TAY–SACHS DISEASE FORECAST IN 19 MAJOR MARKETS 2018–2028

  • $ 5577
  • July 2018
  • 78 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Tay Sachs Disease (TSD) in 19 Major Markets Hexosaminidase A deficiency (HEX A deficiency) results in a group of neurodegenerative ...

  • Europe
  • Southern Europe
  • Neurological Disorder
  • Industry analysis
  • Life Expectancy

Alzheimer’s Disease KOL Interview – UK

  • $ 599
  • January 2019
  • 14 pages

Overview This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in ...

  • United Kingdom
  • Dementia
  • Industry analysis

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2018

  • $ 3500
  • April 2018
  • 60 pages

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2018 ...

  • World
  • United Kingdom
  • Dementia
  • Hormone
  • Industry analysis
  • Dementia Prevalence
  • Prescription Drug Sales

Major Depressive Disorder KOL Interview – UK

  • $ 599
  • December 2018
  • 11 pages

Overview A UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and ...

  • United Kingdom
  • Depression
  • Industry analysis

EPIOMIC EPIDEMIOLOGY SERIES: AUTISM SPECTRUM DISORDERS FORECAST IN 22 MAJOR MARKETS 2018–2028

  • $ 5577
  • April 2018
  • 88 pages

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Autism Spectrum Disorders in 22 Major Markets Autism Spectrum Disorders (ASD) or Pervasive Developmental Disorder (PDD) defines a group of ...

  • Europe
  • Northern Europe
  • Mental Health
  • Industry analysis
  • Birth Rate

EPIOMIC EPIDEMIOLOGY SERIES: EPILEPSY FORECAST IN 19 MAJOR MARKETS 2018–2028

  • $ 5577
  • April 2018
  • 86 pages

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Epilepsy in 19 Major Markets Epilepsy is a complex neurologic disorder characterised by the occurrence of seizures, divided into several types ...

  • South Korea
  • Italy
  • Neurological Disorder
  • Industry analysis
  • Diagnostic Imaging Density

EPIOMIC EPIDEMIOLOGY SERIES: RETT SYNDROME FORECAST IN 23 MAJOR MARKETS 2018–2028

  • $ 5577
  • April 2018
  • 52 pages

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Rett Syndrome in 23 Major Markets Rett syndrome (RTT) is a rare neurodevelopmental disorder characterised by loss of acquired skills afte ...

  • South Korea
  • United Kingdom
  • Neurological Disorder
  • Industry analysis
  • Life Expectancy

EPIOMIC EPIDEMIOLOGY SERIES: SCHIZOPHRENIA FORECAST IN 27 MAJOR MARKETS 2018–2028

  • $ 5577
  • April 2018
  • 92 pages

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Schizophrenia in 27 Major Markets Schizophrenia is a mental illness characterised by psychosis, apathy and withdrawal, as well as cognitive ...

  • Europe
  • Northern Europe
  • Psychotic Disorder
  • Epidemiology
  • Industry analysis
  • Schizophrenia Prevalence
  • Smoking Prevalence

University of Edinburgh - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 43 pages

Summary University of Edinburgh (UE) is an educational service provider that offers undergraduate and postgraduate programs.The university offers courses in the areas of accounting, art, business, chemistry, ...

  • United Kingdom
  • World
  • Dementia
  • Healthcare
  • Industry analysis
  • Dementia Prevalence
  • HIV AIDS Prevalence

University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 102 pages

Summary University College London (UCL), a subsidiary of University of London is an educational institute that provides undergraduate, post-graduate, and life learning programs.The institute offers programs ...

  • United Kingdom
  • England
  • Therapy
  • Healthcare
  • Industry analysis
  • Drug Approval
  • Biologics Production

Enterome Bioscience SA - Product Pipeline Analysis, 2018 Update

  • $ 750
  • September 2018
  • 38 pages

Summary Enterome Bioscience SA (Enterome) is a drug development company that develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases.The company develops ...

  • World
  • United States
  • Digestive System Disorder
  • Diagnostics
  • Industry analysis
  • Medical Devices Sales

IRLAB Therapeutics AB (IRLAB A) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 44 pages

Summary IRLAB Therapeutics AB (IRL) is a pharmaceutical company that discovers and develops drugs to treat central nervous system associated diseases.The company conducts flagship technology integrative ...

  • United Kingdom
  • Finland
  • Psychotic Disorder
  • Therapy
  • Industry analysis
  • Outpatient Visits
  • Medical Technology Density

Randox Laboratories Ltd - Product Pipeline Analysis, 2018 Update

  • $ 750
  • August 2018
  • 45 pages

Summary Randox Laboratories Ltd (Randox) is a clinical diagnostic company that manufactures and provides clinical diagnostic solutions to laboratories.The company’s products include biochip analyzers, ...

  • Northern Ireland
  • In Vitro Diagnostic Reagent
  • Dementia
  • Industry analysis
  • Hospital Admission
  • Medical Devices Sales

Actinogen Medical Ltd (ACW) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 65 pages

Summary Actinogen Medical Ltd (Actinogen), formerly Actinogen Ltd is a biotechnology company that develops novel treatments for alzheimer’s disease and the cognitive decline associated with neurodegenerative ...

  • United Kingdom
  • Dementia
  • Clinical Trial
  • Industry analysis
  • Dementia Prevalence
  • Drug Approval

Avacta Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 68 pages

Avacta Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s Avacta Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments ...

  • United Kingdom
  • Private Placement
  • Mental Health
  • Quarterly report
  • Company
  • Dates Price

EPIOMIC EPIDEMIOLOGY SERIES: LOWER URINARY TRACT SYMPTOMS FORECAST IN 12 MAJOR MARKETS 2018–2028

  • $ 4808
  • December 2017
  • 52 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lower Urinary Tract Symptoms In 12 Major Markets Lower urinary tract symptoms (LUTS) are a standardised group of symptoms related ...

  • United States
  • United Kingdom
  • Neurological Disorder
  • Industry analysis
  • Overweight Prevalence

EPIOMIC EPIDEMIOLOGY SERIES: PARKINSON’S DISEASE FORECAST IN 19 MAJOR MARKETS 2018–2028

  • $ 5577
  • December 2017
  • 78 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Parkinson’s Disease in 19 Major Markets Parkinson’s disease (PD) is a neurodegenerative disorder that seriously affects everyday ...

  • Japan
  • South Korea
  • Psychotic Disorder
  • Industry analysis
  • Dementia Incidence
  • Health Insurance Claims

EPIOMIC EPIDEMIOLOGY SERIES: MILD COGNITIVE IMPAIRMENT FORECAST IN 14 MAJOR MARKETS 2017–2027

  • $ 4808
  • November 2017
  • 50 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Mild Cognitive Impairment in 14 Major Markets Mild cognitive impairment (MCI) is a condition in which a person has problems with memory, ...

  • Italy
  • Japan
  • Dementia
  • Industry analysis
  • Dementia Prevalence
  • Diagnostic Imaging Density

EPIOMIC EPIDEMIOLOGY SERIES: NIEMANN–PICK TYPE C DISEASE FORECAST IN 11 MAJOR MARKETS 2017–2027

  • $ 4808
  • November 2017
  • 54 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Niemann–Pick Type C Disease in 11 Major Markets Niemann–Pick type C (NP-C) disease is a rare autosomal recessive lysosomal storage ...

  • United Kingdom
  • United States
  • Neurological Disorder
  • Hospital
  • Industry analysis
  • Hospital Admission
  • Mortality Rate

NPS+ (EU5) [MS]

  • $ 2844
  • November 2017
  • 1 pages

How does your multiple sclerosis brand stack up against the competition? There are various options available to EU5 neurologists to treat multiple sclerosis. Clearly some of these options are achieving ...

  • Europe
  • Spain
  • Neurological Disorder
  • Industry analysis

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

  • $ 3995
  • October 2017
  • 37 pages

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026 Summary Alzheimer’s disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, ...

  • United Kingdom
  • Spain
  • Dementia
  • Industry analysis
  • Dementia Prevalence
  • Elderly Population

Multiple Sclerosis: Update Bulletin #1 [February 2018]

  • $ 1151
  • February 2018
  • 1 pages

This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab) has been approved ...

  • Europe
  • United Kingdom
  • Neurological Disorder
  • Industry analysis

Medical Affairs Reputations (EU5) [Parkinson’s Disease]

  • $ 6755
  • October 2017
  • 1 pages

How well does your Parkinson’s Disease medical affairs team performance compare with the rest? According to this latest survey of 150 neurologists across the EU5 (UK, France, Germany, Italy and Spain) ...

  • Europe
  • Spain
  • Psychotic Disorder
  • Health Care Provider
  • Industry analysis
  • Practising Physicians

Drug Overview: Latuda

  • $ 10000
  • April 2018
  • 33 pages

Drug Overview  Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. ...

  • Europe
  • European Union
  • Antipsychotic
  • Cardiovascular Drug
  • Industry analysis

Market Access Impact: Multiple Sclerosis (EU5) 2017

  • $ 5637
  • July 2017
  • 1 pages

Market barriers affect nearly 15% of multiple sclerosis prescriptions in the EU5 In the EU5 countries, market barriers affect a modest 15% of multiple sclerosis prescriptions, but they’re giving market ...

  • Spain
  • France
  • Neurological Disorder
  • Industry analysis

Epiomic Epidemiology Series: Myasthemia Gravis Forecast in 26 Major Markets 2017-2027

  • $ 4741
  • April 2017
  • 92 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Myasthenia Gravis in 26 Major Markets Myasthenia Gravis (MG), also known as autoimmune myasthenia, is one of the most significant ...

  • South Korea
  • Italy
  • Neurological Disorder
  • Epidemiology
  • Industry analysis
  • Hospital Discharge
  • Hospital Admission

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on